Fireside Chat with Dr. Mikael Dolsten
Day two of the BIO CEO & Investor Conference kicked off with a Fireside Chat featuring Mikael Dolsten, MD, Phd, president, worldwide research & development from Pfizer, Inc and moderated by...
View ArticleValue Drivers Under the Influence – How Licensing and Key Events Affect...
The Tuesday plenary luncheon at the 2012 BIO CEO & Investor Conference featured a panel of experts representing several perspectives on valuation. The session opened with Ben Bonifant, Senior Vice...
View ArticleFive Keys to Making Biotech Flourish in China
As China positions itself as a major global player in the international biotechnology arena, it has included biotechnology as one of the seven strategic priorities for scientific and technological...
View ArticleBIO 2012 Super Session Recap: Ernst & Young’s Beyond Borders
The fanfare surrounding this morning’s unveiling of Ernst & Young’s 26th annual report on the state of the biotech industry, Beyond Borders, was buoyed by positive trends outlined in the report...
View ArticleWhat Will It Take for the U.S. to Maintain Leadership in the Biopharma Industry?
The biopharmaceutical industry is an important contributor to U.S. economic growth and sustainability, with more than 650,000 direct jobs (supporting a total of nearly 4 million jobs) and an economic...
View ArticleResearch: Working Together Toward Cures
Modern biomedical innovation and the discovery of new cures and therapies for devastating diseases require robust collaboration and coordination among industry, research institutions and physicians. By...
View ArticleData Exclusivity Protects Innovators and Assures Investors
Biotechnology companies must have some certainty that they can protect their investment in the development of new breakthrough therapies for a substantial period of time. This protection helps...
View ArticleHow to Survive the Patent Cliff: Eli Lilly’s CEO at the BIO CEO & Investor...
Like a number of companies, Eli Lilly is confronting a wave of patent expirations called the patent cliff. The company lost U.S. patent protection on the anti-psychotic Zyprexa in the fall of 2011 and...
View ArticleThe Pivotal Role the Public Market Plays in Financing R&D
Growing innovators are the heart of our industry. Biotech small businesses face a dual struggle – the daily challenge of running a growing company combined with the roadblocks intrinsic to...
View ArticlePatents Improve Public Health: Progressive Economy Reviews TRIPS at 20 Years
Progressive Economy released a research paper examining the effect of TRIPS (Trade-Related Aspects of Intellectual Property) on global health. Here are their findings quoted from their press release:...
View ArticleWanted: Tax Policies to Support Innovation
Innovative small businesses work to advance research, development, and manufacturing of technologies to help solve economic, environmental, and societal challenges. The Coalition of Small Business...
View ArticleSynthetic Biology: The Sword in the Stone to Defeat Devastating Diseases
On July 17th, 2014 the House held a hearing titled: Subcommittee on Research and Technology Hearing – Policies to Spur Innovative Medical Breakthroughs from Laboratories to Patients Witnesses Dr....
View ArticleUpcoming Panel will Highlight The Successes of The NCATS Tech Transfer Model
On October 29, 2014 the Center for Clean Energy Innovation and the House Technology Transfer Caucus will be hosting a panel of experts to discuss NIH’s NCATS program and its impact on the tech transfer...
View ArticleBIO Deputy General Counsel Testifies on Patent Reform
On Wednesday, March 18, BIO’s Deputy Counsel for Intellectual Property, Hans Sauer, testified in front of the U.S. Senate Judiciary Committee regarding proposed reforms to the current U.S. patent...
View ArticleThe International Space Station Brings Big Buzz and Big Science to BIO 2015
This year, the BIO International Convention will raise the bar, yet again, through a collaborative effort with CASIS and NASA to showcase space research at this year’s convention. CASIS, the nonprofit...
View ArticleBIO Is Almost Here – What To Consider Before Entering New Therapeutic Areas
Over the past decade, the biopharmaceutical industry has witnessed a shift towards specialty care. From 2008 to 2014, FDA specialty drug approvals jumped from 33 percent to over 50 percent of all...
View Article
More Pages to Explore .....